Cargando…

Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials

Aim: Anti-angiogenesis agents have been added as maintenance therapy in ovarian cancer over the past decade. The aim of this meta-analysis was to analyze the efficacy of anti-angiogenesis therapy in newly diagnosed and relapsed ovarian cancer. Methods: PubMed, Embase, and Cochrane databases were sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yizi, Zhang, Shitai, Song, Zixuan, Ouyang, Ling, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636101/ https://www.ncbi.nlm.nih.gov/pubmed/34867330 http://dx.doi.org/10.3389/fphar.2021.726278

Ejemplares similares

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
por: Colombo, Nicoletta, et al.
Publicado: (2021)

Statin use and the risk of ovarian and endometrial cancers: a meta-analysis
por: Wang, Yizi, et al.
Publicado: (2019)

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
por: Nag, Shona, et al.
Publicado: (2022)

Prognostic Significance of Systematic Lymphadenectomy in Patients With Optimally Debulked Advanced Ovarian Cancer: A Meta-Analysis
por: Wang, Yizi, et al.
Publicado: (2020)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
por: DiSilvestro, Paul, et al.
Publicado: (2021)

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
por: Monk, Bradley J., et al.
Publicado: (2022)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis
por: Xu, Xiaoyu, et al.
Publicado: (2019)

Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
por: Lee, Banghyun, et al.
Publicado: (2023)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
por: Kunos, Charles A., et al.
Publicado: (2020)

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4
por: Gao, Ying, et al.
Publicado: (2022)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

IMT-05 PHASE III RANDOMIZED CLINICAL TRIAL OF AFTV FOR NEWLY DIAGNOSED GLIOBLASTOMA
por: Nitta, Masayuki, et al.
Publicado: (2019)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Yizi, et al.
Publicado: (2022)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yuping, et al.
Publicado: (2016)

The Effect of Transcranial Direct Current Stimulation on Relapse, Anxiety, and Depression in Patients With Opioid Dependence Under Methadone Maintenance Treatment: A Pilot Study
por: Sadeghi Bimorgh, Mohammad, et al.
Publicado: (2020)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
por: Ayoub, Nehad M., et al.
Publicado: (2022)

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
por: Moore, Kathleen N., et al.
Publicado: (2021)

Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States
por: Chen, Jigang, et al.
Publicado: (2021)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Survival After Minimally Invasive vs. Open Radical Hysterectomy for Cervical Cancer: A Meta-Analysis
por: Wang, Yizi, et al.
Publicado: (2020)

Editorial: Angiogenesis and Nutraceuticals
por: Trabalzini, Lorenza, et al.
Publicado: (2022)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
por: Zhou, Hui, et al.
Publicado: (2019)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Social Interaction With Relapsed Partner Facilitates Cocaine Relapse in Rats
por: Meng, Shiqiu, et al.
Publicado: (2021)

Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study
por: Song, Zixuan, et al.
Publicado: (2022)

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
por: Sun, Chun-yan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s3qcmadrnicub3houjr0r2k7n9